Latest profit margin for Upstream Bio: -5712.33% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for UPB is -5712.33% as of September 2026. That compares with -4366.77% in the prior-year period — down 30.8% year over year. That is below the Healthcare sector average of 21.75%. Investors often review this figure alongside Upstream Bio's historical trend and sector peers before judging valuation or financial health.
Over the past year, UPB's profit margin moved from -4366.77% to -5712.33% — a 30.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Upstream Bio's valuation or profitability profile.
Against Healthcare companies, UPB currently prints -5712.33% for profit margin, while the sector average sits near 21.75%. That is roughly 26367.4% below the sector mean. Large gaps often invite a closer look at Upstream Bio's growth, margins, and balance sheet.
Profit Margin shows how effectively Upstream Bio converts resources into returns. At -5712.33%, UPB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4366.77% in the prior-year period — down 30.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting UPB's profit margin (-5712.33%), review year-over-year change from -4366.77%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.